Endo International plc announced that its Board of Directors has appointed Jennifer M. Chao to serve as a director, effective immediately. Ms. Chao has also been appointed to Endo's Audit Committee and its Compliance Committee and becomes the eighth independent director on Endo's expanded ten member Board. Ms. Chao will stand for election by Endo's shareholders at the Company's 2021 Annual General Meeting. Ms. Chao has over 25 years of experience in the biotech and life sciences industries focused primarily on finance and corporate strategy. She is the founder of CoreStrategies Management, LLC, which provides corporate and financial consulting to biotech and life sciences companies. Most recently, Ms. Chao served as Chairman of the Board of BioSpecifics Technologies Corp. until its acquisition by Endo in December 2020. Additionally, Ms. Chao has experience in investment research, most recently serving as Managing Director and Senior Lead Biotechnology Securities Analyst at Deutsche Bank where she covered large- and small- to mid-cap biotechnology companies.